Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma - art. no. e798

Matthews, GM, Lefebure, M, Doyle, MA, Shortt, J, Ellul, J, Chesi, M, Banks, KM, Vidacs, E, Faulkner, D, Atadja, P, Bergsagel, PL and Johnstone, RW (2013) Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma - art. no. e798. CELL DEATH & DISEASE.

Item Type: Article
Additional Information: pubid: 178 nvp_institute: NIBR contributor_address: Peter MacCallum Canc Ctr, Gene Regulat Lab, East Melbourne, Vic 3002, Australia, Univ Melbourne, Sir Peter MacCallum Dept Oncol, East Melbourne, Vic, Australia geoff.matthews@petermac.org; Peter MacCallum Canc Ctr, Bioinformat Core Facil, East Melbourne, Vic 3002, Australia ; Mayo Clin Arizona, Ctr Comprehens Canc, Scottsdale, AZ USA, Mayo Clin Arizona, Scottsdale, AZ USA ; Peter MacCallum Canc Ctr, Dept Pathol, East Melbourne, Vic 3002, Australia ; Novartis Inst Biomed Res, Cambridge, MA USA ; Peter MacCallum Canc Ctr, Gene Regulat Lab, East Melbourne, Vic 3002, Australia; Univ Melbourne, Sir Peter MacCallum Dept Oncol, East Melbourne, Vic, Australia; Matthews, G M; Peter MacCallum Canc Ctr, Gene Regulat Lab, St Andrews Pl, East Melbourne, Vic 3002, Australia
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22000

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.